Cognitive assessment in patients with hepatitis C submitted to treatment with sofosbuvir and simeprevir or daclatasvir Avaliação cognitiva em pacientes com hepatite C submetidos ao tratamento com sofosbuvir e simeprevir ou daclatasvir

Página do item simplificado
dc.contributor.authorGascon M.R.P.
dc.contributor.authorBenute G.R.G.
dc.contributor.authorMacedo E.C.
dc.contributor.authorCapitao C.G.
dc.contributor.authorVidal J.E.
dc.contributor.authorSmid J.
dc.contributor.authorMarcusso R.M.N.
dc.contributor.authorde Lucia M.C.S.
dc.contributor.authorPenalva-De-Oliveira A.C.
dc.contributor.authorDiament D.
dc.date.accessioned2024-03-12T23:47:35Z
dc.date.available2024-03-12T23:47:35Z
dc.date.issued2020
dc.description.abstract© 2020 Associacao Arquivos de Neuro-Psiquiatria. All rights reserved.Background:Hepatitis C can be defined as an infectious disease that develops an inflammatory activity,which may cause an impairment in the central nervous system, may cause cognitive impairments and symptoms of depression. Objective: The objective of this study was to verify the cognitive performance of patients with chronic hepatitis C before and after treatment with simeprevir, sofosbuvir, and daclatasvir. Methods: A prospective study was carried out in three stages: before, right after treatment, and six months after. Fifty-eight patients under clinical follow-up were evaluated at the Emílio Ribas Infectology Institute, in São Paulo, Brazil. The following instruments were used: sociodemographic questionnaire, Lawton's Scale, Beck's Depression Inventory, and a battery of neuropsychological tests that evaluated: intellectual function, memory, attention, executive function, and motor and processing speed). For statistical analysis, the analyses described (mean, frequency, and standard deviation), chi-square, and ANOVA were used. Results: Most of the participants were male (n=30, 51.7%), with a mean of 58.23±8.79 years, mean schooling of 9.75±4.43 years. Comparing the results of neuropsychological evaluations (before, just after completion of drugs, and six months), a significant improvement was observed in relation to the acquisition of new knowledge (p=0.03), late visual memory (p=0.01), and tendency towards alternate attention (p=0.07). Conclusion: The treatment of the hepatitis C virus improved cognitive performance, especially in relation to memory.
dc.description.firstpage342
dc.description.issuenumber7
dc.description.lastpage348
dc.description.volume78
dc.identifier.doi10.1590/0004-282X20200022
dc.identifier.issn1678-4227
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/34957
dc.relation.ispartofArquivos de Neuro-Psiquiatria
dc.rightsAcesso Aberto
dc.subject.otherlanguageCognitive Disorders
dc.subject.otherlanguageCombined Modality Therapy
dc.subject.otherlanguageHepatitis C
dc.titleCognitive assessment in patients with hepatitis C submitted to treatment with sofosbuvir and simeprevir or daclatasvir Avaliação cognitiva em pacientes com hepatite C submetidos ao tratamento com sofosbuvir e simeprevir ou daclatasvir
dc.typeArtigo
local.scopus.citations4
local.scopus.eid2-s2.0-85087532620
local.scopus.subjectAntiviral Agents
local.scopus.subjectBrazil
local.scopus.subjectCognition
local.scopus.subjectDrug Therapy, Combination
local.scopus.subjectGenotype
local.scopus.subjectHepacivirus
local.scopus.subjectHumans
local.scopus.subjectImidazoles
local.scopus.subjectMale
local.scopus.subjectProspective Studies
local.scopus.subjectSimeprevir
local.scopus.subjectSofosbuvir
local.scopus.subjectTreatment Outcome
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85087532620&origin=inward
Arquivos
Coleções
Artigos de periódico